HG Capital Leads Series D Round In MicuRx Pharmaceuticals

August 5, 2020 — 13:53 CST

This Data Is Locked!

This area is available only to Subscribers.

MicuRx Pharmaceuticals, a Chinese clinical-stage antimicrobial drug developer, has secured a RMB300 million (US$43.11 million) series D round of financing led by HG Capital. Zero2IPO... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Related Data:

Bahrain’s Investcorp Targets RMB2-4 Billion Buyout Fund in China

November 25, 2023 — 00:58

Middle Eastern Sovereign Wealth Funds Deepen Investment in China

November 10, 2023 — 23:35

AI-Driven Pharmaceutical Startups Attract Soaring Investor Interest

November 5, 2023 — 03:24

Yufeng Capital: Expect To Live To 120 Years As China Realizes Digital Healthcare

April 24, 2021 — 04:25

China, With 1.4 Billion People, Faces Looming Demographic Crisis

February 18, 2021 — 04:48

What Are China’s Tech Giants: Alibaba, Tencent, Baidu, JD, Doing In Internet Healthcare?

January 30, 2021 — 05:58

Sequoia China Leads $150 Million Round In Drug Developer Visen Pharma

January 13, 2021 — 08:47

Trustbridge Partners Leads $500 Million Round In Digital Healthcare Firm Dingxiangyuan

December 29, 2020 — 05:43

Tencent, Jeneration Capital Leads RMB2 Billion Round In Medbanks

December 22, 2020 — 04:08